Results of a placebo-controlled double blind randomised trial to investigate the efficacy of rifaximin-α versus placebo in improving systemic inflammation in patients with cirrhosis and chronic hepatic encephalopathy (RIFSYS Trial)

Activity: Talk or presentationOral presentation

Description

Gut-Liver Axis Monothematic Meeting (Leuven, Belgium), European Association for the Study of the Liver
Period2018
Held at1. European Association for the Study of the Liver
Degree of RecognitionInternational